Chronic IOP elevation affects cerebrovascular reactivity in murine visual cortex, linked to widespread brain changes

Article

Investigators from the New York University Grossman School of Medicine presented data at the ARVO 2022 annual meeting that concluded mapping of the relative cerebrovascular reactivity in the murine brain showed widespread brain changes resulting from the chronic IOP elevation and demonstrates vascular involvement in glaucoma both within and beyond the primary visual pathways.

Chronic IOP elevation affects cerebrovascular reactivity in murine visual cortex, linked to widespread brain changes

A team of investigators from the New York University Grossman School of Medicine found in a murine model of experimental glaucoma that chronic IOP elevation had a role in the widespread vascular and functional brain changes seen in the animals, according to a presentation

Dr Kevin Chan, an assistant professor at the New York University Grossman School of Medicine, presented the study results at the Association for Research in Vision and Ophthalmology’s 2022 annual meeting in Denver, Colorado, United States, on behalf of Dr Russell Chan, also affiliated with the school.

They hypothesized that the vascular functions of the visual cortex and basal forebrain are involved in glaucoma, because the former has lower choline levels in glaucoma and the latter has cholinergic projections to the visual cortex for modulating the cerebral blood flow and visual processing, they explained.

In a recent experiment, they used resting-state functional magnetic resonance imaging (rsfMRI) to document the relative cerebrovascular reactivity in the brain, specifically, decreased reactivity in the visual cortex and increased reactivity in the basal forebrain in patients in whom the severity of the glaucoma was progressing. The speculation was that a chronic increase in IOP may lead to cerebrovascular reactivity changes in the brains of patients with glaucoma and visual impairment.

The authors conducted the current murine experiment with the goal of elucidating the mechanisms involved. To do so, they administered an intracameral injection of cross-linking hydrogel to the right eye of the mice to obstruct the aqueous outflow and induce a chronically elevated IOP. Untreated mice served as controls. The IOP was measured in both eyes of the mice 2 to 3 times weekly for 3 weeks and measured the optomotor responses of the animals and conducted rsfMRI experiments.

Effects of chronic IOP elevation

The increase in IOP was induced and sustained in the murine right eyes. The cerebrovascular reactivity decreased in the left untreated eye but not in the right visual cortex and the cerebrovascular reactivity increased in the right basal forebrain in the glaucoma model but not in the control mice.

The authors reported that the IOP in the injected eye was correlated inversely with the relative cerebrovascular reactivity in the left visual cortex and correlated positively with the relative cerebrovascular reactivity in the right basal forebrain. The optomotor responses indicated a decrease in the visual acuity and an increase in the visual contrast threshold in the injected eye, indicating visual impairment. The visual acuity decrease was correlated inversely with the relative cerebrovascular reactivity in the basal forebrain.

The authors concluded that this mapping of the relative cerebrovascular reactivity in the murine brain showed widespread brain changes resulting from the chronic IOP elevation and demonstrates vascular involvement in glaucoma both within and beyond the primary visual pathways.

“Our results showed similar patterns of relative cerebrovascular reactivity changes as those seen in glaucoma patients along with visual impairments, indicating a role of chronic IOP elevation in the widespread vascular and functional brain changes in experimental glaucoma,” the authors concluded.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.